Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Trial try to assess the efficacy of dasatinib in terms of major molecular response rate at 6
months in patients with CP-CML who have achieved complete cytogenetic response without major
molecular response after at least 18 months on Imatinib 400/600.